Bank Julius Baer & Co. Ltd Zurich Sells 6,880 Shares of Thermo Fisher Scientific Inc. $TMO

Bank Julius Baer & Co. Ltd Zurich reduced its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 11.1% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 54,964 shares of the medical research company’s stock after selling 6,880 shares during the quarter. Bank Julius Baer & Co. Ltd Zurich’s holdings in Thermo Fisher Scientific were worth $31,849,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in the business. JPL Wealth Management LLC bought a new position in Thermo Fisher Scientific during the third quarter valued at about $28,000. Beacon Financial Strategies CORP bought a new stake in Thermo Fisher Scientific in the fourth quarter worth about $29,000. Olistico Wealth LLC bought a new position in shares of Thermo Fisher Scientific during the 4th quarter valued at approximately $29,000. Cloud Capital Management LLC purchased a new stake in shares of Thermo Fisher Scientific during the 3rd quarter worth approximately $31,000. Finally, KERR FINANCIAL PLANNING Corp purchased a new position in Thermo Fisher Scientific in the third quarter valued at approximately $38,000. 89.23% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research firms have issued reports on TMO. DZ Bank assumed coverage on Thermo Fisher Scientific in a research report on Friday, March 27th. They issued a “buy” rating and a $610.00 target price for the company. Wells Fargo & Company decreased their price objective on Thermo Fisher Scientific from $675.00 to $615.00 and set an “overweight” rating for the company in a report on Friday, May 8th. Royal Bank Of Canada set a $490.00 price objective on Thermo Fisher Scientific in a research note on Thursday. Wall Street Zen lowered shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research report on Saturday, May 9th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Thermo Fisher Scientific in a research report on Wednesday, April 8th. Two analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat, Thermo Fisher Scientific has a consensus rating of “Buy” and an average target price of $616.10.

Thermo Fisher Scientific Trading Up 0.5%

Thermo Fisher Scientific stock opened at $448.12 on Friday. The company has a debt-to-equity ratio of 0.77, a quick ratio of 1.15 and a current ratio of 1.53. Thermo Fisher Scientific Inc. has a fifty-two week low of $385.46 and a fifty-two week high of $643.99. The stock has a market cap of $166.53 billion, a P/E ratio of 24.64, a PEG ratio of 1.97 and a beta of 0.88. The firm’s fifty day moving average price is $487.50 and its 200-day moving average price is $542.85.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Thursday, April 23rd. The medical research company reported $5.44 EPS for the quarter, topping the consensus estimate of $5.25 by $0.19. Thermo Fisher Scientific had a return on equity of 16.86% and a net margin of 15.15%.The business had revenue of $11.01 billion during the quarter, compared to analysts’ expectations of $10.86 billion. During the same period in the previous year, the business earned $5.15 earnings per share. The firm’s revenue was up 6.2% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. Equities research analysts forecast that Thermo Fisher Scientific Inc. will post 24.86 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Wednesday, April 15th. Investors of record on Friday, March 13th were paid a $0.47 dividend. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.43. This represents a $1.88 dividend on an annualized basis and a yield of 0.4%. The ex-dividend date of this dividend was Friday, March 13th. Thermo Fisher Scientific’s payout ratio is 10.34%.

Insider Activity at Thermo Fisher Scientific

In other news, CEO Marc N. Casper sold 5,000 shares of Thermo Fisher Scientific stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $512.40, for a total transaction of $2,562,000.00. Following the completion of the sale, the chief executive officer directly owned 123,925 shares of the company’s stock, valued at approximately $63,499,170. The trade was a 3.88% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, COO Gianluca Pettiti sold 400 shares of the stock in a transaction on Monday, April 27th. The shares were sold at an average price of $462.66, for a total value of $185,064.00. Following the completion of the transaction, the chief operating officer directly owned 25,051 shares in the company, valued at approximately $11,590,095.66. This represents a 1.57% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 0.33% of the company’s stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.